These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 31376137)

  • 1. Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment.
    Koschorke A; Faraci S; Giani D; Chiodoni C; Iorio E; Canese R; Colombo MP; Lamolinara A; Iezzi M; Ladomery M; Vernieri C; de Braud F; Di Nicola M; Tagliabue E; Castagnoli L; Pupa SM
    Cell Oncol (Dordr); 2019 Dec; 42(6):815-828. PubMed ID: 31376137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer.
    Castagnoli L; Ghedini GC; Koschorke A; Triulzi T; Dugo M; Gasparini P; Casalini P; Palladini A; Iezzi M; Lamolinara A; Lollini PL; Nanni P; Chiodoni C; Tagliabue E; Pupa SM
    Oncogene; 2017 Mar; 36(12):1721-1732. PubMed ID: 27641338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of phenethyl isothiocyanate in HER2-positive breast cancer models.
    Gupta P; Srivastava SK
    BMC Med; 2012 Jul; 10():80. PubMed ID: 22824293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer-preventive effect of phenethyl isothiocyanate through tumor microenvironment regulation in a colorectal cancer stem cell xenograft model.
    Shin JM; Lim E; Cho YS; Nho CW
    Phytomedicine; 2021 Apr; 84():153493. PubMed ID: 33626429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancer.
    Tang H; Song C; Ye F; Gao G; Ou X; Zhang L; Xie X; Xie X
    J Cell Mol Med; 2019 Dec; 23(12):8114-8127. PubMed ID: 31599500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenethyl isothiocyanate upregulates death receptors 4 and 5 and inhibits proliferation in human cancer stem-like cells.
    Wang D; Upadhyaya B; Liu Y; Knudsen D; Dey M
    BMC Cancer; 2014 Aug; 14():591. PubMed ID: 25127663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
    Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
    Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenethyl isothiocyanate suppresses cancer stem cell properties in vitro and in a xenograft model.
    Yun JH; Kim KA; Yoo G; Kim SY; Shin JM; Kim JH; Jung SH; Kim J; Nho CW
    Phytomedicine; 2017 Jul; 30():42-49. PubMed ID: 28545668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The landscape of d16HER2 splice variant expression across HER2-positive cancers.
    Volpi CC; Pietrantonio F; Gloghini A; Fucà G; Giordano S; Corso S; Pruneri G; Antista M; Cremolini C; Fasano E; Saggio S; Faraci S; Di Bartolomeo M; de Braud F; Di Nicola M; Tagliabue E; Pupa SM; Castagnoli L
    Sci Rep; 2019 Mar; 9(1):3545. PubMed ID: 30837627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells.
    Koziel JE; Herbert BS
    Breast Cancer Res Treat; 2015 Feb; 149(3):607-18. PubMed ID: 25627551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenethyl Isothiocyanate Exposure Promotes Oxidative Stress and Suppresses Sp1 Transcription Factor in Cancer Stem Cells.
    Upadhyaya B; Liu Y; Dey M
    Int J Mol Sci; 2019 Feb; 20(5):. PubMed ID: 30818757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).
    Martin-Castillo B; Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Moreno JM; Corominas-Faja B; Urruticoechea A; Martín ÁG; López-Bonet E; Menendez JA
    Cell Cycle; 2013 Jan; 12(2):225-45. PubMed ID: 23255137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts.
    Cufi S; Corominas-Faja B; Vazquez-Martin A; Oliveras-Ferraros C; Dorca J; Bosch-Barrera J; Martin-Castillo B; Menendez JA
    Oncotarget; 2012 Apr; 3(4):395-8. PubMed ID: 22565037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenethyl isothiocyanate inhibits colorectal cancer stem cells by suppressing Wnt/β-catenin pathway.
    Chen Y; Li Y; Wang XQ; Meng Y; Zhang Q; Zhu JY; Chen JQ; Cao WS; Wang XQ; Xie CF; Li XT; Geng SS; Wu JS; Zhong CY; Han HY
    Phytother Res; 2018 Dec; 32(12):2447-2455. PubMed ID: 30159926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.
    Martin-Castillo B; Lopez-Bonet E; Cuyàs E; Viñas G; Pernas S; Dorca J; Menendez JA
    Oncotarget; 2015 Oct; 6(32):32317-38. PubMed ID: 26474458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EPHA5 mediates trastuzumab resistance in HER2-positive breast cancers through regulating cancer stem cell-like properties.
    Li Y; Chu J; Feng W; Yang M; Zhang Y; Zhang Y; Qin Y; Xu J; Li J; Vasilatos SN; Fu Z; Huang Y; Yin Y
    FASEB J; 2019 Apr; 33(4):4851-4865. PubMed ID: 30620624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells.
    Chihara Y; Shimoda M; Hori A; Ohara A; Naoi Y; Ikeda JI; Kagara N; Tanei T; Shimomura A; Shimazu K; Kim SJ; Noguchi S
    Breast Cancer Res Treat; 2017 Nov; 166(1):55-68. PubMed ID: 28702892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2 decreases drug sensitivity of ovarian cancer cells via inducing stem cell-like property in an NFκB-dependent way.
    Wang W; Gao Y; Hai J; Yang J; Duan S
    Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30314995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flubendazole overcomes trastuzumab resistance by targeting cancer stem-like properties and HER2 signaling in HER2-positive breast cancer.
    Kim YJ; Sung D; Oh E; Cho Y; Cho TM; Farrand L; Seo JH; Kim JY
    Cancer Lett; 2018 Jan; 412():118-130. PubMed ID: 29080749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intratumor lactate levels reflect HER2 addiction status in HER2-positive breast cancer.
    Castagnoli L; Iorio E; Dugo M; Koschorke A; Faraci S; Canese R; Casalini P; Nanni P; Vernieri C; Di Nicola M; Morelli D; Tagliabue E; Pupa SM
    J Cell Physiol; 2019 Feb; 234(2):1768-1779. PubMed ID: 30132876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.